Although changing a cold tumor into a hot tumor remains a great challenge, an increasing number of pioneer studies focusing on the mechanisms of the immunosuppressive microenvironment and PD-1/PD-L1 blockade combination treatment have shed light on a brilliant future of EOC treatment. This evidence concerns the gene PDCD1 and neoplasm.